Taelman, Vincent; Radojewski, Piotr; Marincek, Nicolas; Ben-Shlomo, Anat; Grotzky, Andrea; Olariu, Cristina I; Perren, Aurel; Stettler, Christoph; Krause, Thomas Michael; Meier, Lorenz; Cescato, Renzo; Walter, Martin A. (2016). Upregulation of Key Molecules for Targeted Imaging and Therapy. Journal of nuclear medicine, 57(11), pp. 1805-1810. Society of Nuclear Medicine 10.2967/jnumed.115.165092
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
1805.full.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB) |
Targeted diagnosis and therapy enable precise tumor detection and treatment. Successful examples for precise tumor targeting are diagnostic and therapeutic radioligands. However, patients with tumors expressing low levels of the relevant molecular targets are deemed ineligible for such targeted approaches.
METHODS
We performed a screen for drugs that upregulate the somatostatin receptor subtype 2 (sstr2). Then, we characterized the effects of these drugs on transcriptional, translational, and functional levels in vitro and in vivo.
RESULTS
We identified 9 drugs that act as epigenetic modifiers, including the inhibitor of DNA methyltransferase decitabine as well as the inhibitors of histone deacetylase tacedinaline and romidepsin. In vitro, these drugs upregulated sstr2 on transcriptional, translational, and functional levels in a time- and dose-dependent manner. Thereby, their combinations revealed synergistic effects. In vivo, drug-based sstr2 upregulation improved the tumor-to-background and tumor-to-kidney ratios, which are the key determinants of successful sstr2-targeted imaging and radiopeptide therapy.
CONCLUSION
We present an approach that uses epigenetic modifiers to improve sstr2 targeting in vitro and in vivo. Translation of this method into the clinic may potentially convert patients ineligible for targeted imaging and therapy to eligible candidates.
Actions (login required)
 |
Edit item |